Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Maori with asthma

Respirology

Volumn 19, Issue 6, 2014, Pages 842-851

  Pilcher, Janine ^a,b   Patel, Mitesh ^a,b,c   Smith, Ann ^d   Davies, Cheryl ^d   Pritchard, Alison ^a   Travers, Justin ^a   Black, Peter ^e   Weatherall, Mark ^b,e   Beasley, Richard ^a,b,e   Harwood, Matire ^f  

^a WELLINGTON HOSPITAL   (New Zealand)

^b Capital and Coast District Health Board ^*  (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d Tu Kotahi Maori Asthma Trust   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

asthma; health disparity; M ori; randomized controlled trial; single combination budesonide formoterol inhaler as maintenance and reliever therapy

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; SALBUTAMOL; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; ETHNICITY; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); METERED DOSE INHALER; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; DRUG COMBINATION; ETHNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEBULIZER; NEW ZEALAND; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NEW ZEALAND; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904572948     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12319     Document Type: Article

References (40)

1. Robson B, Harris R, Hauora: Màori Standards of Health IV. A study of the years 2000-2005. 2007.
2. Ministry of Health. Tatau Kahukura: Maori Health Chart Book 2010, 2nd edn. Ministry of Health, Wellington, 2010.
3. Lewis S, Hales S, Slater T, Pearce N, Crane J, Beasley R,. Geographical variation in the prevalence of asthma symptoms in New Zealand. N. Z. Med. J. 1997; 110: 286-289.
4. Crane J, Lewis S, Slater T, Crossland L, Robson B, D'Souza W, Pearce N, Town GI, Garrett J, Armstrong R,. The self reported prevalence of asthma symptoms amongst adult New Zealanders. N. Z. Med. J. 1994; 107: 417-421.
5. Ellison-Loschmann L, Cheng S, Pearce N,. Time trends and seasonal patterns of asthma deaths and hospitalisations among Maori and non-Maori. N. Z. Med. J. 2002; 115: 6-9.
6. Ellison-Loschmann L, King R, Pearce N,. Regional variations in asthma hospitalisations among Maori and non-Maori. N. Z. Med. J. 2004; 117: U745.
7. Garrett JE, Mulder J, Wong-Toi H,. Reasons for racial differences in A & E attendance rates for asthma. N. Z. Med. J. 1989; 102: 121-124.
8. Jenkins CR, Chang AB, Poulos LM, Marks GB,. Asthma in Indigenous Australians: so much yet to do for Indigenous lung health. Med. J. Aust. 2009; 190: 530-531.
9. Netuveli G, Hurwitz B, Levy M, Fletcher M, Barnes G, Durham SR, Sheikh A,. Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet 2005; 365: 312-317.
10. Gorman BK, Chu M,. Racial and ethnic differences in adult asthma prevalence, problems, and medical care. Ethn. Health 2009; 14: 527-552.
11. Ospina MB, Voaklander DC, Stickland MK, King M, Senthilselvan A, Rowe BH,. Prevalence of asthma and chronic obstructive pulmonary disease in Aboriginal and non-Aboriginal populations: a systematic review and meta-analysis of epidemiological studies. Can. Respir. J. 2012; 19: 355-360.
12. Pomare E, Tutengaehe H, Ramsden I, Hight M, Pearce N, Ormsby V,. Asthma in Maori people. N. Z. Med. J. 1992; 105: 469-470.
13. Ellison-Loschmann L, Pearce N,. He Mate Huango: an update on Maori asthma. Pac. Health Dialog 2000; 7: 82-93.
14. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, Buhl R,. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract. 2007; 61: 725-736.
15. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED,. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129-136.
16. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG,. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753.
17. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherall M, et-al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32-42.
18. National Asthma Council Australia. Symbicort SMART Asthma Action Plan. From http://www.nationalasthma.org.au/health-professionals/tools-for-primary- care/asthma-action-plans/asthma-action-plan-library. [Accessed 28 June 2012].
19. Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R,. Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J. Allergy Clin. Immunol. 2012; 130: 1420-1422.
20. Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, Weatherall M, Beasley R,. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin. Immunol. Pract. 2013; 1: 83-91.
21. Ministry of Health. Ethnicity Data Protocols for the Health and Disability Sector. Ministry of Health, Wellington, 2004.
22. Holt S, Masoli M, Beasley R,. The use of the self-management plan system of care in adult asthma. Prim. Care Respir. J. 2004; 13: 19-27.
23. Balanag VM, Yunus F, Yang PC, Jorup C,. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther. 2006; 19: 139-147.
24. Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A,., Selross O,. Formoterol turbuhaler as reliever medication in patients with acute asthma. Eur. Respir. J. 2006; 27: 735-741.
25. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, et-al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59-99.
26. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR,. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902-907.
27. Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Kallen A,. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J. Allergy Clin. Immunol. 1998; 101: 312-319.
28. Brown RW, O'Brien CD, Martin UJ, Uryniak T, Lampl KL,. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial. J. Allergy Clin. Immunol. 2012; 130: 362-379.
29. Wechsler ME, Castro M, Lehman E, Chinchilli VM, Sutherland ER, Denlinger L, Lazarus SC, Peters SP, Israel E,. Impact of race on asthma treatment failures in the asthma clinical research network. Am. J. Respir. Crit. Care Med. 2011; 184: 1247-1253.
30. Selak V, Crengle S, Elley CR, Wadham A, Harwood M, Rafter N, Bullen C, Pillai A, Arroll B, Rodgers A,. Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial. Int. J. Equity Health 2013; 12: 1-6.
31. Vogelmeier C, Naya I, Ekelund J,. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study. Clin. Drug Investig. 2012; 32: 439-449.
32. Fraser PM, Speizer FE, Waters SD, Doll R, Mann NM,. The circumstances preceding death from asthma in young people in 1968 to 1969. Br. J. Dis. Chest 1971; 65: 71-84.
33. Beasley R, Pearce N, Crane J, Burgess C,. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J. Allergy Clin. Immunol. 1999; 104: S18-30.
34. Ministry of Health. Kōrero Mārama: Health Literacy and Māori Results from the 2006 Adult Literacy and Life Skills Survey. Ministry of Health, Wellington, 2010.
35. Ford ES, Mannino DM, Redd SC, Moriarty DG, Mokdad AH,. Determinants of quality of life among people with asthma: findings from the Behavioral Risk Factor Surveillance System. J. Asthma 2004; 41: 327-336.
36. Beasley R, D'Souza W, Te Karu H, Fox C, Harper M, Robson B, Howden-Chapman P, Crane J, Burgess C, Woodman K, et-al. Trial of an asthma action plan in the Maori community of the Wairarapa. N. Z. Med. J. 1993; 106: 336-338.
37. D'Souza W, Crane J, Burgess C, Te Karu H, Fox C, Harper M, Robson B, Howden-Chapman P, Crossland L, Woodman K, et-al. Community-based asthma care: trial of a 'credit card' asthma self-management plan. Eur. Respir. J. 1994; 7: 1260-1265.
38. D'Souza WJ, Slater T, Fox C, Fox B, Te Karu H, Gemmell T, Ratima MM, Pearce NE, Beasley RB,. Asthma morbidity 6 yrs after an effective asthma self-management programme in a Maori community. Eur. Respir. J. 2000; 15: 464-469.
39. Ratima MM, Fox C, Fox B, Te Karu H, Gemmell T, Slater T, D'Souza WJ, Pearce NE,. Long-term benefits for Maori of an asthma self-management program in a Maori community which takes a partnership approach. Aust. N. Z. J. Public Health 1999; 23: 601-605.
40. Statistics New Zealand. Māori population estimates. 2012. From http://www.stats.govt.nz/browse-for-stats/population/estimates-and-projections/ maori-population-estimates.aspx [Accessed 27 December 2012].